Dawson James Maintains a Buy Rating on Anavex Life Sciences (AVXL)
January 05 2022 - 04:10AM
TipRanks
Dawson James analyst Jason Kolbert maintained a Buy rating on
Anavex Life Sciences (AVXL – Research Report) on November 24 and
set a price target of $35.00. The company's shares closed last
Tuesday at $16.24. According to TipRanks.com, Kolbert has currently
0 stars on a ranking scale of 0-5 stars, with an average return of
-7.6% and a 35.5% success rate. Kolbert covers the Healthcare
sector, focusing on stocks such as Brainstorm Cell Therapeutics,
Citius Pharmaceuticals, and Sorrento Therapeutics. Anavex Life
Sciences has an analyst consensus of Strong Buy, with a price
target consensus of $39.80, implying a 123.0% upside from current
levels.
https://www.tipranks.com/news/blurbs/dawson-james-maintains-a-buy-rating-on-anavex-life-sciences-avxl?utm_source=advfn.com&utm_medium=referral
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2022 to May 2022
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2021 to May 2022